1. Home
  2. GRI vs TRIB Comparison

GRI vs TRIB Comparison

Compare GRI & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRI
  • TRIB
  • Stock Information
  • Founded
  • GRI 2018
  • TRIB 1992
  • Country
  • GRI United States
  • TRIB Ireland
  • Employees
  • GRI N/A
  • TRIB N/A
  • Industry
  • GRI Biotechnology: Pharmaceutical Preparations
  • TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GRI Health Care
  • TRIB Health Care
  • Exchange
  • GRI Nasdaq
  • TRIB Nasdaq
  • Market Cap
  • GRI 4.9M
  • TRIB 5.4M
  • IPO Year
  • GRI N/A
  • TRIB N/A
  • Fundamental
  • Price
  • GRI $1.77
  • TRIB $0.99
  • Analyst Decision
  • GRI Strong Buy
  • TRIB
  • Analyst Count
  • GRI 2
  • TRIB 0
  • Target Price
  • GRI $22.50
  • TRIB N/A
  • AVG Volume (30 Days)
  • GRI 207.8K
  • TRIB 122.5K
  • Earning Date
  • GRI 11-13-2025
  • TRIB 11-14-2025
  • Dividend Yield
  • GRI N/A
  • TRIB N/A
  • EPS Growth
  • GRI N/A
  • TRIB N/A
  • EPS
  • GRI N/A
  • TRIB N/A
  • Revenue
  • GRI N/A
  • TRIB $61,555,000.00
  • Revenue This Year
  • GRI N/A
  • TRIB $13.51
  • Revenue Next Year
  • GRI N/A
  • TRIB $13.14
  • P/E Ratio
  • GRI N/A
  • TRIB N/A
  • Revenue Growth
  • GRI N/A
  • TRIB 8.31
  • 52 Week Low
  • GRI $1.10
  • TRIB $0.48
  • 52 Week High
  • GRI $22.95
  • TRIB $3.44
  • Technical
  • Relative Strength Index (RSI)
  • GRI 42.57
  • TRIB 44.01
  • Support Level
  • GRI $1.89
  • TRIB $0.88
  • Resistance Level
  • GRI $2.27
  • TRIB $1.10
  • Average True Range (ATR)
  • GRI 0.17
  • TRIB 0.07
  • MACD
  • GRI -0.03
  • TRIB 0.00
  • Stochastic Oscillator
  • GRI 1.96
  • TRIB 47.15

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About TRIB Trinity Biotech plc

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Share on Social Networks: